Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1
暂无分享,去创建一个
Dean Y. Li | W. Hauswirth | M. Shibuya | J. Ambati | Leah A. Owen | Y. Le | P. Lacal | K. Chalam | Yingbin Fu | Subrata K. Das | N. Ferrara | G. Gao | W. Baehr | R. Albuquerque | S. Grisanti | K. Thomas | V. Chiodo | B. Ambati | Dean Y Li | Nirbhai Singh | H. Uehara | J. Baffi | Tadashi R. Miya | Derick G. Holt | David J. Wilson | A. Bastos-Carvalho | A. Orecchia | Xiaohui Zhang | Ling Luo | Thomas Olsen | K. Jackman | Wei Huang | C. Mamalis | J. Simonis | Faisal Ahmed | Kim, Young-hee | Nirbhai Singh
[1] W. Ji,et al. Effect of low dose bisphenol A on the early differentiation of human embryonic stem cells into mammary epithelial cells. , 2013, Toxicology letters.
[2] S. P. Srinivas,et al. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. , 2013, ACS nano.
[3] T. Pawson,et al. Soluble FLT1 Binds Lipid Microdomains in Podocytes to Control Cell Morphology and Glomerular Barrier Function , 2012, Cell.
[4] A. Kijlstra,et al. AAV2-Mediated Subretinal Gene Transfer of mIL-27p28 Attenuates Experimental Autoimmune Uveoretinitis in Mice , 2011, PloS one.
[5] Holger Gerhardt,et al. Basic and Therapeutic Aspects of Angiogenesis , 2011, Cell.
[6] Samir Sissaoui,et al. Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis , 2011, Vascular cell.
[7] P. Carmeliet,et al. Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.
[8] Ivana K. Kim,et al. In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography. , 2011, Investigative ophthalmology & visual science.
[9] H. Grossniklaus,et al. Age-Related Retinopathy in NRF2-Deficient Mice , 2011, PloS one.
[10] Ivana K. Kim,et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] R. Braun,et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration , 2011, Nature.
[12] M. Schachner,et al. Short DNA sequences inserted for gene targeting can accidentally interfere with off‐target gene expression , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] L. Groome,et al. Proteases and sFlt-1 release in the human placenta. , 2010, Placenta.
[14] M. Rajappa,et al. Ocular angiogenesis: mechanisms and recent advances in therapy. , 2010, Advances in clinical chemistry.
[15] Magali Saint-Geniez,et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris , 2009, Proceedings of the National Academy of Sciences.
[16] G. Alessio,et al. Combined cataract extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age‐related macular degeneration , 2009, Journal of cataract and refractive surgery.
[17] K. Becker,et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis , 2009, Proceedings of the National Academy of Sciences.
[18] Shuliang Jiao,et al. Retinal tumor imaging and volume quantification in mouse model using spectral-domain optical coherence tomography. , 2009, Optics express.
[19] Christian Fischer,et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.
[20] Magali Saint-Geniez,et al. Endogenous VEGF Is Required for Visual Function: Evidence for a Survival Role on Müller Cells and Photoreceptors , 2008, PloS one.
[21] G. Pertile,et al. Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation , 2008, British Journal of Ophthalmology.
[22] Christian Ahlers,et al. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. , 2008, Ophthalmology.
[23] Victoria L. Bautch,et al. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching , 2008, The Journal of cell biology.
[24] I. Bhutto,et al. Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration. , 2008, Archives of ophthalmology.
[25] Justine R. Smith,et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.
[26] D. Zack,et al. Inducible expression of cre recombinase in the retinal pigmented epithelium. , 2008, Investigative ophthalmology & visual science.
[27] Paul G. Updike,et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. , 2007, Investigative ophthalmology & visual science.
[28] P. Sieving,et al. Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration. , 2007, Investigative ophthalmology & visual science.
[29] K. Rajewsky,et al. Vagaries of conditional gene targeting , 2007, Nature Immunology.
[30] P. Jani,et al. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier , 2006, British Journal of Ophthalmology.
[31] Toxic alert , 2007, Nature.
[32] Kei Shinoda,et al. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Martin Collinson,et al. Corneal avascularity is due to soluble VEGF receptor-1 , 2006, Nature.
[34] F. Peale,et al. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. , 2006, Blood.
[35] M. C. Donati,et al. Retinal Angiomatous Proliferation: Association with Clinical and Angiographic Features , 2005, Ophthalmologica.
[36] I. Constable,et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[37] H. Ghandehari,et al. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] P. Campochiaro,et al. Nonviral ocular gene transfer , 2005, Gene Therapy.
[39] J. Ott,et al. Complement Factor H Polymorphism in Age-Related Macular Degeneration , 2005, Science.
[40] Y. Sauve,et al. Rhodopsin‐iCre transgenic mouse line for Cre‐mediated rod‐specific gene targeting , 2005, Genesis.
[41] Bart Landuyt,et al. Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.
[42] Frank Schaeffel,et al. A paraxial schematic eye model for the growing C57BL/6 mouse , 2004, Vision Research.
[43] A. Bill,et al. Physiology of the choroidal vascular bed , 1983, International Ophthalmology.
[44] Eiji Sakurai,et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice , 2003, Nature Medicine.
[45] P. Lacal,et al. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for theα 5β1 integrin , 2003, Journal of Cell Science.
[46] M. Seeliger,et al. Long‐term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV‐mediated gene replacement therapy , 2003, The journal of gene medicine.
[47] Martin Friedlander,et al. MOUSE MODEL OF SUBRETINAL NEOVASCULARIZATION WITH CHOROIDAL ANASTOMOSIS , 2003, Retina.
[48] Sonia H Yoo,et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. , 2003, Survey of ophthalmology.
[49] U. Storb,et al. Insertion of Phosphoglycerine Kinase (Pgk)-Neo 5′ of Jλ1 Dramatically Enhances Vjλ1 Rearrangement , 2001, The Journal of experimental medicine.
[50] R. D'Amato,et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. , 2001, The American journal of pathology.
[51] A Kijlstra,et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. , 1999, The American journal of pathology.
[52] M Aguet,et al. VEGF is required for growth and survival in neonatal mice. , 1999, Development.
[53] T. Noda,et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[54] P. Campochiaro,et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. , 1997, The American journal of pathology.
[55] R. Kendall,et al. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.
[56] J. Rossant,et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.
[57] R. Frank,et al. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. , 1994, Investigative ophthalmology & visual science.
[58] R. Kendall,et al. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.